Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.33 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401745 | 1.00 | LMNA (0.45) | LMNACACNA1HBACE1NAMPTMEN1 | |
| SCHEMBL6403038 | 0.89 | CACNA1H (0.41) | LMNACACNA1HMEN1KMT2AMAPT | |
| SCHEMBL6407165 | 0.84 | CA1 (0.40) | — | |
| SCHEMBL6401746 | 0.79 | LMNA (0.42) | LMNACACNA1HPPARG | |
| SCHEMBL6401744 | 0.78 | LMNA (0.38) | LMNACACNA1HBACE1OPRM1OPRD1 | |
| SCHEMBL6404595 | 0.76 | LMNA (0.48) | LMNANAMPTMEN1KMT2AMAPT | |
| SCHEMBL7253037 | 0.75 | LMNA (0.46) | LMNANAMPTMEN1KMT2APPARG | |
| SCHEMBL6404601 | 0.75 | LMNA (0.46) | LMNANAMPTMEN1KMT2AOPRM1 | |
| SCHEMBL6408728 | 0.74 | AR (0.41) | KMT2AMAPT | |
| SCHEMBL6401373 | 0.74 | MMP3 (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | LMNA 3804/4885CACNA1H 2723/4885BACE1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.